...
首页> 外文期刊>Medicine. >Pre and post-liver transplant outcome of cirrhotic patients with acute on chronic liver failure
【24h】

Pre and post-liver transplant outcome of cirrhotic patients with acute on chronic liver failure

机译:肝硬化患者肝硬化患者的前肝脏移植术治疗慢性肝衰竭

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Acute on chronic liver failure (ACLF) is a dynamic syndrome, but frequently associated with a high 1 month mortality rate. This is the first study applying the new European Association for the Study of the Liver- chronic liver failure consortium criteria to explore mortality on the waiting list (WL) and early after liver transplantation (LT) in a cohort of Romanian cirrhotic patients that improved or recovered after an episode of ACLF. To assess frequency and waitlist mortality for different grades of ACLF. An observational study was conducted; 257 patients with liver cirrhosis included on the WL between 2015 and 2017 were analyzed. The cumulative incidence of waitlist mortality or removal was calculated for combination of competing events using multivariable competing risks regression. ACLF-1 occurred in 12.07%, ACLF-2 in 7.39% and ACLF-3 in 8.56% of patients. Median Model for End Stage Liver Diseases (MELD) score at the moment of ACLF was 29. The main event while on the WL was death, followed by ACLF; patients with ACLF-3 had a significantly greater subhazard ratio for mortality of 2.25 (1.55–3.26) compared to patients with ACLF-1 or 2. LT proved to be associated with a significantly lower risk of death on the WL at 6 months after inclusion. One and 12 months post-transplant survival of patients with or without ACLF was similar ( P = .77). Occurrence of an ACLF episode while on the WL is associated with a significantly high mortality rate, as well as MELD score at inclusion on the WL, renal and liver failure, presence of hepatic encephalopathy. Overall patient short and long term survival after LT is similar to non-ACLF patients in good selected cases.
机译:慢性肝功能衰竭(ACLF)是一种动态综合征,但经常与高1个月死亡率相关联。这是应用新欧洲肝脏慢性肝脏失效联盟标准研究的第一项研究,以探讨等候名单(WL)和肝移植队(LT)提前改善或改善的诉讼患者的死亡率在ACLF的一集之后恢复。评估不同等级的ACLF等级的频率和候补死亡率。进行了观察研究;分析了257例肝硬化患者,2015年至2017年间WL患者。使用多变量竞争风险回归计算竞争事件的组合计算等候性死亡率或去除的累积发生率。 ACLF-1发生在12.07%,ACLF-2中,7.39%和ACLF-3,患者的8.56%。在ACLF时期肝脏疾病(融合)分数的中位模型是29.在WL上的主要活动是死亡,其次是ACLF;与ACLF-1或2患者相比,ACLF-3的患者的死亡率显着更大的2.25(1.55-3.26)的死亡率显着更大。(1.55-3.26),并被证明在包容后6个月内与WL的死亡风险显着降低。移植患者的一次和12个月,或不含ACLF的患者的存活率相似(P = .77)。在WL上发生ACLF发作的发生与显着高的死亡率相关,以及在包含WL,肾病和肝功能衰竭,肝脑病存在下的融合得分。总体患者短期和长期存活后LT在良好选定病例中的非ACLF患者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号